Mr. Gros has been Managing Director at Novartis Venture Funds in Basel, Switzerland since 2016. Previously, he held various senior positions in intellectual property at Nestlé, Pasteur Mérieux Connaught and Novartis. Mr. Gros currently serves on the boards of Adicet (US), Anokion (CH), Atlas Genetics (UK), Kanyos (US), Inflazome (IE), Vivet Therapeutics (FR) and Opsona (IE). His prior investments, which have resulted in the successful acquisition and IPO listings, include: Altimmune, Evolva, Gensight, Merus, Neovacs, Okairos and Tigenix. Mr. Gros is a Kaufmann Fellow and holds a Biotechnology Engineering Masters Degree in France. He also holds European and French patent lawyer degrees, and a Masters Degree in Private Law.